UBS AM
CPRX

UBS AM’s Catalyst Pharmaceutical CPRX Stock Holding History

UBS AM’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.93M Buy
284,154
+3,265
+1% +$96.4K ﹤0.01% 1306
2026
Q1 		$6.95M Buy
280,889
+1,608
+0.6% +$38.3K ﹤0.01% 1404
2025
Q4 		$6.52M Buy
279,281
+1,980
+0.7% +$44.1K ﹤0.01% 1326
2025
Q3 		$5.46M Sell
277,301
-308,370
-53% -$6.34M ﹤0.01% 1330
2025
Q2 		$12.7M Buy
585,671
+59,374
+11% +$1.4M ﹤0.01% 1240
2025
Q1 		$12.8M Buy
526,297
+262,392
+99% +$5.91M ﹤0.01% 1128
2024
Q4 		$5.51M Buy
263,905
+27,683
+12% +$595K ﹤0.01% 1560
2024
Q3 		$4.7M Sell
236,222
-14,898
-6% -$276K ﹤0.01% 1608
2024
Q2 		$3.89M Buy
251,120
+135,376
+117% +$2.11M ﹤0.01% 1630
2024
Q1 		$1.84M Buy
115,744
+255
+0.2% +$3.84K ﹤0.01% 1721
2023
Q4 		$1.94M Hold
115,489
– – ﹤0.01% 1707
2023
Q3 		$1.35M Sell
115,489
-21,588
-16% -$289K ﹤0.01% 1798
2023
Q2 		$2.27M Hold
137,077
– – ﹤0.01% 1582
2023
Q1 		$2.27M Buy
137,077
+10,126
+8% +$167K ﹤0.01% 1582
2022
Q4 		$2.36M Buy
126,951
+5,814
+5% +$89.5K ﹤0.01% 1456
2022
Q3 		$1.55M Sell
121,137
-831
-0.7% -$9.85K ﹤0.01% 1727
2022
Q2 		$855K Sell
121,968
-3,790
-3% -$27.8K ﹤0.01% 2054
2022
Q1 		$1.04M Sell
125,758
-38,900
-24% -$275K ﹤0.01% 2116
2021
Q4 		$1.11M Buy
164,658
+26,983
+20% +$177K ﹤0.01% 2156
2021
Q3 		$730K Sell
137,675
-64,800
-32% -$354K ﹤0.01% 2324
2021
Q2 		$1.16M Buy
202,475
+7,474
+4% +$38.6K ﹤0.01% 2130
2021
Q1 		$899K Hold
195,001
– – ﹤0.01% 2146
2020
Q4 		$651K Buy
195,001
+97,700
+100% +$328K ﹤0.01% 2194
2020
Q3 		$289K Sell
97,301
-2,852
-3% -$11.2K ﹤0.01% 2314
2020
Q2 		$463K Sell
100,153
-490
-0.5% -$2.2K ﹤0.01% 2156
2020
Q1 		$387K Buy
100,643
+6,881
+7% +$28.2K ﹤0.01% 2072
2019
Q4 		$352K Sell
93,762
-13,759
-13% -$64.3K ﹤0.01% 2334
2019
Q3 		$571K Buy
107,521
+31,148
+41% +$166K ﹤0.01% 2225
2019
Q2 		$293K Buy
+76,373
New +$330K ﹤0.01% 2423

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM's CPRX Position: Q2 2026 in Review

UBS AM increased its Catalyst Pharmaceutical (CPRX) stake by 1.2% in Q2 2026, buying an estimated $96.4K and bringing the position to 284,154 shares worth $8.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

UBS AM first reported a position in CPRX in Q2 2019 and has held it in 29 quarters since. The position peaked at $12.8M in Q1 2025. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • UBS AM held 284,154 shares of Catalyst Pharmaceutical worth $8.93M as of Q2 2026.
  • UBS AM bought 3,265 Catalyst Pharmaceutical shares in Q2 2026, an estimated $96.4K.
  • Catalyst Pharmaceutical made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1306 holding.
  • UBS AM first reported a position in Catalyst Pharmaceutical in Q2 2019 and has held it in 29 quarters since.
  • UBS AM's Catalyst Pharmaceutical position peaked at $12.8M in Q1 2025.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.